Septerna Therapeutics’ Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that’s leaving the market. Potential rival therapies are all injectables.For a certain hormone deficiency inadequately managed with calcium and vitamin supplements, the only FDA-approved therapy is a […]
